- Stocks
- Healthcare
- NASDAQ: IONS

Price (delayed)

$35.86

Market cap

$5.06B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$3.86

Enterprise value

$5.81B

Ionis Pharmaceuticals is a biotechnology company based in Carlsbad, California that specializes in discovering and developing RNA-targeted therapeutics. The company has 3 commercially approved medicines: Spinraza , Tegsedi , and

IONS's quick ratio is down by 31% year-on-year but it is up by 13% since the previous quarter

The company's debt has surged by 62% YoY and by 39% QoQ

The company's equity has shrunk by 58% YoY and by 14% QoQ

What are the main financial stats of IONS

Market
Valuations
Earnings

Shares outstanding

141.15M

Market cap

$5.06B

Enterprise value

$5.81B

Price to earnings (P/E)

N/A

Price to book (P/B)

8.68

Price to sales (P/S)

7.35

EV/EBIT

N/A

EV/EBITDA

N/A

EV/Sales

8.44

Revenue

$687.72M

EBIT

-$193.48M

EBITDA

-$176.79M

Free cash flow

-$52.77M

Per share
Balance sheet
Liquidity

EPS

-$3.86

Free cash flow per share

-$0.37

Book value per share

$4.13

Revenue per share

$4.88

TBVPS

$17.51

Total assets

$2.5B

Total liabilities

$1.91B

Debt

$1.31B

Equity

$582.67M

Working capital

$1.94B

Debt to equity

2.25

Current ratio

7.62

Quick ratio

7.09

Net debt/EBITDA

-4.22

Margins
Efficiency
Dividend

EBITDA margin

-25.7%

Gross margin

98.3%

Net margin

-78.8%

Operating margin

-32.6%

Return on assets

-21.2%

Return on equity

-64%

Return on invested capital

-7.2%

Return on capital employed

-8.8%

Return on sales

-28.1%

Dividend yield

N/A

DPS

N/A

Payout ratio

N/A

How has the Ionis Pharmaceuticals stock price performed over time

Intraday

-0.94%

1 week

-0.91%

1 month

-9.51%

1 year

-26.37%

YTD

-36.58%

QTD

-10.1%

How have Ionis Pharmaceuticals's revenue and profit performed over time

Revenue

$687.72M

Gross profit

$675.79M

Operating income

-$224.14M

Net income

-$541.96M

Gross margin

98.3%

Net margin

-78.8%

The gross profit is down by 28% year-on-year and by 2.8% since the previous quarter

IONS's revenue is down by 27% YoY and by 2.8% QoQ

The company's net margin fell by 15% QoQ

The operating margin has declined by 14% since the previous quarter

What is Ionis Pharmaceuticals's growth rate over time

What is Ionis Pharmaceuticals stock price valuation

P/E

N/A

P/B

8.68

P/S

7.35

EV/EBIT

N/A

EV/EBITDA

N/A

EV/Sales

8.44

Ionis Pharmaceuticals's EPS has decreased by 11% QoQ

The company's equity has shrunk by 58% YoY and by 14% QoQ

The stock's price to book (P/B) is 42% less than its 5-year quarterly average of 15.2

The P/S is 33% less than the 5-year quarterly average of 11.0 and 16% less than the last 4 quarters average of 8.8

IONS's revenue is down by 27% YoY and by 2.8% QoQ

How efficient is Ionis Pharmaceuticals business performance

Ionis Pharmaceuticals's return on sales has decreased by 46% QoQ

Ionis Pharmaceuticals's ROIC has decreased by 44% from the previous quarter

IONS's return on equity is down by 38% since the previous quarter

IONS's return on assets is down by 18% since the previous quarter

What is IONS's dividend

DPS

N/A

Dividend yield

N/A

Payout ratio

N/A

There are no recent dividends present for IONS.

How did Ionis Pharmaceuticals financials performed over time

The total assets is 30% greater than the total liabilities

IONS's quick ratio is down by 31% year-on-year but it is up by 13% since the previous quarter

The current ratio has declined by 30% year-on-year but it rose by 13% since the previous quarter

The company's debt is 125% higher than its equity

Ionis Pharmaceuticals's debt to equity has soared by 63% from the previous quarter

The company's debt has surged by 62% YoY and by 39% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.